Experts see a future in EBV-related disease vaccination
About 9 of every 10 people are believed to be infected with Epstein-Barr Virus (EBV). When infected as juveniles, the virus is associated with several diseases, ranging from mononucleosis to various cancers and more.
According to an article written collectively by directors from the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID), the National Cancer Institute (NCI) and other experts, a vaccine that could prevent EBV infection may not be possible with current understanding of the virus, but it might be possible to develop an EBV vaccine that could prevent diseases associated with EBV infection, including forms of lymphoma including Hodgkins lymphoma as well as Burkitt's lymphoma, the latter among the most aggressive of all cancers.
The article outlined the direction future research should take in this regard, and it includes looking for bio-markers that would help doctors predict EBV-related cancer development and widespread collaboration among experts in government, industry, and academia to develop that EBV vaccine.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
